MD Anderson, Pfizer Launch Immuno-Oncology Collaboration
The University of Texas MD Anderson Cancer Center will join with Pfizer to study novel combinations of three of the pharma giant’s immuno-oncology candidates and other Pfizer treatments for solid and blood cancers, the partners said today, through a collaboration whose value was not disclosed. The collaboration will consist of multiple studies—the first of which is envisioned to enroll up to 188 patients with solid tumors , who will be placed in seven different treatment groups of immuno-oncology agents alone or immuno-oncology agents combined with radiotherapy. The second study will include eight different treatment groups and is expected to enroll up to 159 patients with acute myeloid leukemia (AML) undergoing treatment at MD Anderson. Three additional studies are planned to evaluate investigational Pfizer agents in patients with blood cancers. The majority of the trials are expected to open in late 2017. “This alliance aims to define ...
Original Article: MD Anderson, Pfizer Launch Immuno-Oncology Collaboration
